Autologous CD34+ and CD133+ stem cells transplantation in patients with end stage liver disease

Table 3 Biochemical changes in the studied groups (mean ± SD)

	Pre treatment	1st month	2nd month	3rd month	6th month
Bilirubin (mg%)
Patients	2.51 ± 1.94	2.75 ± 1.66	2.31 ± 1.33	2.34 ± 1.29	2.18 ± 1.28
Control	2.68 ± 1.49	2.80 ± 1.51	2.92 ± 1.71	3.41 ± 1.77	3.58 ± 1.56
			P < 0.001	P < 0.002	P < 0.003
Albumin (gm/dL)
Patients	2.61 ± 0.44	2.73 ± 0.62	2.83 ± 0.39	2.92 ± 0.33	2.94 ± 0.45
Control	2.69 ± 0.26	2.60 ± 0.30	2.54 ± 0.25	2.44 ± 0.35	2.10 ± 0.34
				P < 0.04	P < 0.001
PC (%)
Patients	46.2 ± 12.5	49.6 ± 12.5	55.0 ± 14.5	54.9 ± 12.9	56.1 ± 15.7
Control	45.1 ± 12.8	44.9 ± 13.1	42.2 ± 13.5	40.9 ± 14.1	35.8 ± 15.9
		P < 0.005	P < 0.005	P < 0.005	P < 0.005
AST (U/L)
Patients	78.2 ± 32.1	67.4 ± 25.2	68.0 ± 20.2	61.0 ± 18.7	69.0 ± 29.2
Control	75.4 ± 35.2	77.2 ± 30.1	72.1 ± 32.3	75.5 ± 33.3	80.2 ± 32.4
		P < 0.002	P < 0.002	P < 0.003	P < 0.003
ALT (U/L)
Patients	51.5 ± 25.5	45.7 ± 19.6	50.9 ± 27.7	42.8 ± 16.1	47.0 ± 21.3
Control	60.1 ± 20.4	62.5 ± 21.2	66.1 ± 25.1	63.5 ± 23.7	23.7 ± 22.1
		P < 0.001	P < 0.001	P < 0.01	P < 0.01

PC: Prothrombin concentration; AST: Aspartate transaminase; ALT: Alanine transaminase.